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Round Table I
Immunization and Treatment
Convenors: M. YOSHIOKA, Tokyo, AND P. WHITTLESTONE, Cambridge
Contributors: H. MIZUTANI, Tokyo: M. pneumoniae: Immune Mechanisms
W. MASIGA, Kenya: M. mycoides subsp. mycoides Vaccination
C. HOWARD, Compton: M. dispar and M. bovis Vaccination
I. NONOMURA, Gifu: M. synoviae Immunization
R. ROSS, Ames: M. hyopneumoniae Immunization
E. HAYATSU AND M. YOSHIOKA, Tokyo: M. pneumoniae
Immunization
M. MURATA, Fukuyama: M. gallisepticum: Treatment with
Antibiotics
The invited contributors to the immunization section of the round table made the
following main points.
Dr. Mizutani stressed that although both specific antibodies and cellular immune
responses develop in the course of infections, the significance of the different re-
sponses varies widely according to the particular infection. He and colleagues had
previously suggested that in pneumonia caused byMycoplasmapneumoniae there is
a relationship between the degree of the cellular immune responses and the pul-
monary infiltrations which develop during the course of the disease. Recently their
studies had revealed, by means ofthe ELISA test, the presence ofrheumatoid factor
(RF) in the sera of patients with M. pneumoniae infection. RF was present fre-
quently in patients, and individual patients' RF levels fluctuated according to the
clinical stage of the illness, which suggested that RF was related to the immune
response to M. pneumoniae infection.
Dr. Masiga traced the development of vaccines for contagious bovine pleuro-
pneumonia from 1850 to the present day. The earliest vaccines were infectious
pleural fluid or lymph inoculated subcutaneously, which produced severe re-
actions-albeit less damaging than the natural disease. This type of vaccine was
replaced in the 1920s and 1930s by broth cultures ofvarious attenuated M. mycoides
strains, and, more recently, freeze-dried broth vaccines had become available in
Africa. It is generally considered that the passage level of the vaccine is important,
cultures at less than 16 passages being too virulent and those above 73 passages being
non-immunogenic. Although there have been attempts to develop inactivated vac-
cines, the resultant immunity has been generally disappointing. The mechanisms of
protection against M. mycoides infection are not well understood. There appears to
be no relationship between the levels ofcirculating antibody as measured by comple-
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ment-fixation and growth-inhibition tests. Nevertheless work by Dr. Masiga and
colleagues had shown that transfer of serum did convey some protection to the
recipient cattle. There is also some suggestion that cell-mediated immune responses
play a role in resistance to infection.
Dr. Howard described experiments to immunize calves against respiratory infec-
tion with either M. bovis or M. dispar strains by injecting killed organisms by
various routes. Protection was assessed, after challenge, by making counts of the
numbers of mycoplasmas in the lungs of the vaccinated calves compared with un-
protected control calves. The intratracheal inoculations consisted of antigen in
saline; the intramuscular and subcutaneous inoculations were antigen mixed with
Freund's complete or incomplete adjuvant. With M. bovis, two inoculations given
intramuscularly or two inoculations intratracheally did not result in any protection,
whereas protection did follow either intramuscular inoculation followed by intra-
tracheal inoculation or three subcutaneous inoculations. Immunity appeared to be
related to antibody in lung washings at the time of challenge, but not to the circulat-
ing antibody level. With M. dispar three subcutaneous injections generated a low
level of protection, whereas no immunity occurred after intramuscular followed by
intratracheal inoculation. Thus M. dispar appeared to be less immunogenic than M.
bovis in young calves.
Dr. Nonomura had studied the capacity of a temperature-sensitive mutant of M.
synoviae to protect chickens against air sacculitis induced with this mycoplasma.
This mutant (MSts44) had been selected by treating the wild strain (1-3SN) with
N-methyl-N'-nitro-N-nitroso guanidine. The mutant would not grow in broth at
39.5°C and was found to be non-pathogenic in bursectomized chickens. The mutant
was stable after five passages through chickens. The intranasal inoculation of
MSts44 in doses in excess of 1041 colony-forming units was found to protect
chickens against experimentaly induced air sacculitis for at least 21 weeks. Before
it is known whether MSts44 can be used as a vaccine, field trials will be needed.
Dr. Ross first reviewed the earlier evidence indicating that vaccination against en-
zootic pneumonia of pigs caused by M. hyopneumoniae might be feasible, since ex-
perimental vaccines had afforded some protection against gross pneumonia and
mycoplasma colonization of the lung. In field trials the vaccines appeared to fail
completely. The author and colleagues had prepared vaccines from strains J and 11
of M. hyopneumoniae killed with 0.15 percent formalin. In one experiment 101,
1010, or 1011 organisms each reduced the extent of pneumonia on subsequent chal-
lenge. In another experiment some protection followed either two intramuscular in-
jections or one intramuscular followed by one intratracheal inoculation.
Dr. Hayatsu reported on work in collaboration with Dr. Yoshioka and reviewed
the evidence for the protective effect of various immunogens against M. pneumoniae
infection. First, it had been shown that the administration of inactivated vaccine to
hamsters lowered the frequency of experimentally induced M. pneumoniae
pneumonia, but in 'field trials in man such vaccines were not very effective (< 67
percent). Live attenuated vaccines had induced significant protection in both
hamsters and human volunteers, but unfortunately such vaccines were not suf-
ficiently attenuated for general use in man. More recently it had been shown that the
vaccination of hamsters with protein and polysaccharide extracted from M.
pneumoniae cells conferred a significant resistance to challenge.
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in Dr. Yoshioka's own experimental study, three doses of an inactivated adjuvant
M. pneumoniae vaccine protected hamsters significantly against challenge and
reduced the level of mycoplasma colonization in the respiratory tract. No
mycoplasmas could be isolated from hamsters that received six doses of vaccine
before challenge. The protective effect persisted for at least six months after the last
vaccination and there was some protection up to ten months. There was a correla-
tion between the resistance to infection and serum antibody titers, especially those
measured by CF. Bronchial washings from hamsters that had received three vaccina-
tions contained a low level of MI antibody. The inoculation of hyperimmune rabbit
serum into hamsters conferred protection against mycoplasma colonization and MI
antibody was detected in bronchial washings. The immune mechanisms against M.
pneumoniae are still unclear, and much research is needed to develop and evaluate
vaccines for use in man.
In the section of the round table concerned with drugs, Dr. Murata reviewed the
published data on the prevention and treatment of M. gallisepticum infection in
chickens with antibiotics, and related this evidence to the recent work of himself and
his colleagues. The minimal inhibitory concentrations of a range of antibiotics
against 85 strains ofM. gallisepticum in vitro have been determined and surveys also
made on the development ofdrug resistance. The prophylactic or therapeutic effect
of spectinomycin, doxycycline, linco-spectin, cephalexin, josamycin, and tylosin
have been tested in vivo using chicks.
The round table discussion concentrated on the problems ofimmunization against
mycoplasmal disease, especially respiratory disease in man and animals. In intro-
ducing the speakers, Dr. Whittlestone said that the great economic importance of
mycoplasma diseases in animals and the absence of effective drug regimes for the
control of the diseases emphasized the importance of work leading to the eventual
development ofgood vaccines. Currently vaccines are available for very few diseases
and even with the well-known vaccines for contagious bovine pleuropneumonia and
related diseases further improvements are desirable. One of the basic problems
stressedby Dr. Yoshioka was that in natural infections, pathogenic mycoplasmas re-
main in the host for a long period, so that it is clear that even the full range of im-
munological reactions to the organism do not easily exclude the mycoplasmas from
the body. On the other hand, once animals have eventually recovered they are
strongly immune to re-infection. The immunity developing following the use of
inactivated vaccines has been disappointingly low, even when antigen had been in-
oculated repeatedly and in combination with adjuvants.
There was discussion on the high cost of inactivated vaccines because of the ex-
pense of the volume of media needed to grow the whole antigen dose. With the con-
tinuous development ofbetter media which would grow mycoplasmas to high titers,
this problem would decrease, at least for some mycoplasmas. It was clear that very
little information is available on therequirements for the maximal stimulation of the
immune system; more data are needed on for, for example, antigen dose, best routes
of inoculation, intervals between doses, numbers of doses, and particularly which
adjuvants are both effective and acceptable. Speakers stressed the need for more
fundamental information on the immune responses to mycoplasmas, so that these
could be measured to assess the effectiveness ofthe immune response to different ex-
perimental vaccines and vaccine regimes. Although, finally, field trials to assess ac-
tual protection would be needed, understanding and measurement of the immune
responses would enable vaccines to be developed more logically and economically.
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The hope was expressed that the recent development of techniques to isolate
mycoplasma antigens would lead to the identification and manipulation ofthose an-
tigens concerned with stimulating the host immune system.
Dr. Barile asked about the different classes of antibody developing in response to
the various vaccine schedules. Dr. Howard replied that in calves previously inocu-
lated with antigen intramuscularly he could detect very little antibody in the respira-
tory tract, but he had detected some IgG1 and IgG2. When intramuscular injection
was followed by intratracheal inoculation of antigen, more antibody could be
detected, which was mainly IgG1 and IgG2 but there was also some IgA, which was
specific for the inoculated mycoplasma. Dr. Howard stressed that the responses
could be different in different species; thus the types ofimmunoglobulins detected in
the respiratory tract of man were not identical with those detected in the calf's
respiratory tract. Dr. Yoshioka emphasized the poor correlation generally found
between measurable circulating antibody and recovery from mycoplasmal disease,
yet passively administered hyperimmune serum often protected hosts well against
experimental infection. He wondered whether there was any explanation for this ap-
parent contradiction.
There was discussion on the inadequacies ofthe experimental inactivated vaccines
so far tested: even the best vaccines have given only partial protection in that they
have only resulted in a reduction of the extent of pneumonia and a lower level of,
mycoplasma colonization (when vaccines were compared with unvaccinated controls
post-challenge).
Dr. Tully suggested that the selection of a mycoplasma at low passage level might
provide a more immunogenic antigen, since antigen concerned with stimulating pro-
tective mechanisms in the host might well be lost during passage in vitro. He also
thought that growing the mycoplasma in tissue culture rather than in broth would be
worth trying.
Dr. Cassell enquired whether there had been any study in domestic animals com-
paring the degrees ofprotection developing in the upper respiratory tract (nasal tur-
binates) compared with the lower tract (trachea and lung). Dr. Howard replied that
in the calf it was easier to protect against lower tract infection with a mycoplasma
than against nasal infection.
Dr. Fernald recalled that in the literature there were fragments of evidence that
sometimes vaccines might actually result in increased susceptibility rather than pro-
tection, and enquired whether there was any additional information. Dr. Ross said
there was one report from Switzerland of an enzootic pneumonia vaccine trial in
which vaccinated and non-vaccinated pigs were moved into an infected environ-
ment; more extensive lesions of enzootic pneumonia developed in the vaccinated
pigs. In a repeat experiment this did not occur.
The possibility of attenuated vaccinal strains reverting to virulence was raised by
Dr. Jordan. With regard to the live M. mycoides vaccines which had been exten-
sively used in the field, Dr. Masiga said that the risk ofreversion must be very small
because of the virtual absence of any positive evidence; there was, however, one
report that the attenuated T, strain regained its pathogenicity after five serial pas-
sages in cattle. Dr. Nonomura said there was no information on the possible reversion
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of the Ts mutant of M. synoviae. Dr. Jordan also enquired whether there was any
evidence of enhanced pathogenicity of the Ts mutant of M. synoviae if it was used
concurrently with other vaccines, e.g., infectious bronchitis or Newcastle disease
virus. Dr. Nonomura said there was no evidence on this point. In reply to a question
from Dr. Jordan, Dr. Nonomura said that theM. synoviaevaccine protected against
synovitis as well as against respiratory disease (during the round table on arthritis,
additional evidence from other species supporting this general thesis was presented).
In conclusion, Dr. Whittlestone expressed the view that because ofthe many diffi-
culties in developing effective inactivated vaccines for mycoplasmal respiratory
disease and because conventionally attenuated vaccines were generally ineffective,
new approaches should be encouraged; the development of Ts mutant vaccines
might be the eventual solution in some diseases, since these vaccines would be ex-
pected to stimulate the defense systems ofthe respiratory tract, and the cost ofcom-
mercial production could be low enough for such vaccines to be cost-effective.